Corvus Pharmaceuticals, Inc. (CRVS) bonds
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Corvus Pharmaceuticals reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Corvus Pharmaceuticals's 10-K for the period ended Aug 31, 2015
Corvus Pharmaceuticals's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Letter of Credit | – | $100.00K |
| Line of Credit | – | $100.00K |
See a number that looks wrong?